Gilead price target lowered to $81 from $84 at Barclays

Barclays analyst Carter Gould lowered the firm’s price target on Gilead to $81 from $84 and keeps an Equal Weight rating on the shares ahead of the Q2 results. The analyst sees “poor” investor sentiment into a “mixed-quarter with few clean beats” for U.S. pharmaceuticals. Eli Lilly (LLY) and Neurocrine Biosciences (NBIX) are the best positioned into the Q2 prints, the analyst tells investors in a research note.